Menu Search
Equities

CEL-SCI Corp

LSRM:DUS

CEL-SCI Corp

Actions
  • Price (EUR)0.667
  • Today's Change-0.005 / -0.74%
  • Shares traded400.00
  • 1 Year change-66.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

  • Revenue in USD (TTM)0.00
  • Net income in USD-29.10m
  • Incorporated1983
  • Employees43.00
  • Location
    CEL-SCI CorpSUITE 802, 8229 BOONE BLVD .VIENNA 22182United StatesUSA
  • Phone+1 (703) 506-9460
  • Fax+1 (703) 506-9471
  • Websitehttps://cel-sci.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.